PCRX (Pacira Pharmaceuticals) Net Profit

Corporate emblem and logo of pacira.com (PCRX)

Pacira BioSciences (PCRX) enjoys high physician trust due to the development of safe non-opioid agents that facilitate patient recovery. This price chart on GURU.Markets illustrates that profit stands at 0.01. However, revenues may decline due to pressure from insurers and the emergence of affordable drug copies. The liposomal delivery method of Exparel is patent-protected, although FDA approval of generics creates medium-term risks.

PCRX (Pacira BioSciences, Inc.) Company Net Income history from 07/04/2022 to 10/29/2026

Financial and market metric breakdowns for Pacira BioSciences, Inc. (PCRX)

- price and consensus price forecast:
Stock Quotes Pacira Corp|PCRX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Pacira Corp|PCRX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Pacira BioSciences|PCRX - Company Book Value|Market-to-Book Ratio pacira.com|PCRX - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Pacira BioSciences|PCRX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Pacira Pharmaceuticals|PCRX - Company Aggregate Debts|Debts to Book Value Pacira Corp|PCRX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Pacira BioSciences|Critical Liquidity Ratio pacira.com
- net income and valuation multiples indicators:
PCRX - Net Profit
Fundamental valuation:PCRX Pacira Corp
Flagship merchandise of Pacira Pharmaceuticals

The development of non-opioid analgesics within localized production minimizes external logistical and geopolitical risks for Pacira BioSciences (PCRX). This metric captures net operating income, stripping the final amount of random market anomalies and one-off transactions. Such filtration allows investors to objectively assess the issuer's actual financial stability. This analysis helps determine the fundamental valuation floor or the risk of overpayment. The company's annual financial result clearly confirms the overall solvency of the business.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Company Net Income Aquestive Therapeutics, Inc. AQST|SCPH (scPharmaceuticals, Inc.) - Profit After Tax|Tectonic - Net Profit|TNXP - Net Profit|SXTC: Net Profit|Net Income Eupraxia Pharmaceuticals Inc.|BHST (BioHarvest Sciences Inc.) - Net Profit|Invizyne Technologies (EXOZ) - Net Financial Result|Company Net Income Oramed Pharmaceuticals (ORMP)|ENTX (enterabio.com) - Final Profit|Net Profit HYFT (MindWalk Holdings)|Net Profit abvcpharma.com ABVC|CPIX: Net Income|Final Profit QNTM (Quantum BioPharma Ltd.)|FGEN: Net Profit|TELO (Telomir Pharmaceuticals Corp) - Company Net Income|RANI (Rani Therapeutics Holdings) - Net Profit|Synergy CHC Corporation (SNYR) - Net Financial Result|Company Net Income Rallybio Corporation (RLYB)|LEXX - Company Net Income|Company Net Income Pulmatrix Corp PULM|Net Financial Result Pheton Holdings Limited (PTHL)|Aptorum - Net Profit|lyratherapeutics.com (LYRA) - Net Income|IBO: Net Profit|TNFA - Net Financial Result|YCBD (cbdMD Inc.) - Net Profit|Company Net Income PainReform Corp PRFX|Company Net Income Altamira Therapeutics (CYTO)|lipella.com - Company Profit|Net Profit OPTN (OptiNose)|PIRS - Net Income|Procaps Group SA - Net Profit|Company Net Income Petros Pharma|Qilian International (QLI) - Company Net Income|SLRN - Net Financial Result|Company Net Income TFF Pharmaceuticals, Inc.